A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis

Homologous recombination deficiency (HRD) has become an important prognostic and predictive biomarker for patients with high-grade serous ovarian cancer who may benefit from poly-ADP ribose polymerase inhibitors (PARPi) and platinum-based therapies. HRD testing provides relevant information to perso...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarischi-Sousa, Rodrigo, Kroll, José Eduardo, Bonaldi, Adriano, Pierry, Paulo Marques, Villela, Darine, Souza, Camila Alves, Silva, Juliana Santos, Bürger, Matheus Carvalho, Oliveira, Felipe Azevedo, de Paula, Marcelo Gomes, Meliso, Fabiana Marcelino, de Almeida, Luiz Gustavo, Monfredini, Priscilla Morais, de Oliveira, Ana Gabriela, Milanezi, Fernanda, Scapulatempo-Neto, Cristovam, Yamamoto, Guilherme Lopes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648202/
https://www.ncbi.nlm.nih.gov/pubmed/37958189
http://dx.doi.org/10.3390/diagnostics13213293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648202/
https://www.ncbi.nlm.nih.gov/pubmed/37958189
http://dx.doi.org/10.3390/diagnostics13213293

Ejemplares similares